ProCE Banner Activity

CE / CME

What’s New in Sickle Cell Disease and Vaso-occlusive Episodes

Podcast Episodes

Sickle cell disease (SCD) is an inherited blood disorder characterized by mutations in the hemoglobin gene, also known as sickle hemoglobin or HbS, which affect the oxygen carrying capacity and leads to deformation of red blood cells. Clumping of deformed red blood cells, white blood cells, and platelets in the microvasculature is associated with painful vaso-occlusive crises or events. These painful events are the primary reason for patients with SCD to visit a healthcare professional (HCP). However, HCPs may not be familiar with the optimal management of SCD-related complications, including painful vaso-occlusive crises. In this second of 2 podcasts episodes, listen to Alison Towerman, RN, MSN, CPNP, and Michael R. DeBaun, MD, MPH discuss available treatment options for the prevention of painful vaso-occlusive events, and provide emergency department and outpatient recommendations on the proper use and indications for hydroxyurea, L-glutamine, and P-selectin blocking antibody crizanlizumab.

Registered Nurses: 0.25 Nursing contact hours, includes 0.25 hour of pharmacology credit Physician Assistants: maximum of 0.25 hours of AAPA Category 1 CME credits

Released: March 25, 2022

Expiration: March 24, 2023

No longer available for credit.

Share

Faculty

Michael R. DeBaun

Michael R. DeBaun, MD, MPH

Director
Vanderbilt-Meharry Center for Excellence in Sickle Cell Disease
Professor
Pediatrics and Medicine
Vice Chair for Clinical and Translational Research
Department of Pediatrics
J.C. Peterson Chair in Pediatrics
Nashville, Tennessee

Alison Towerman

Alison Towerman, RN, MSN, CPNP

Pediatric Nurse Practitioner
Department of Pediatrics
Division of Hematology/Oncology
Washington University School of Medicine in St. Louis
St. Louis, Missouri

Acknowledgement

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Provided by

ProCE Banner

Supporters

Novartis Pharmaceuticals Corporation

Target Audience

NPs, PAs, and nurses in hematology/oncology and emergency medicine

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Identify novel and emerging strategies for management of sickle cell disease and vaso-occlusive pain

  • List factors to consider in the selection of therapy for SCD

Disclosure

All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Dr DeBaun: consultant/speaker/advisory board: Forma, GBT, Novartis, Vertix.

Ms Kirk: consultant/speaker/advisory board: BioMarin.

Ms Towerman has no relevant financial relationships to disclose.

None of the members of the PCE staff have any relevant relationships to disclose.

Instructions for Credit

Participants wishing to earn CE/CME credit must:

  1. Listen to the content in its entirety
  2. Relate the content material to the learning objectives
  3. Complete the post-test and evaluation form

Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of 100%.

The estimated time to complete this activity is 0.25 hours.

Release date: March 25, 2022
Expiration date: March 24, 2023

Format

Podcast

Disclaimer

The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.

Accreditation

PCE

Joint Accreditation Statement

Joint AccreditationIn support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

ANCC Credit Designation

Nursing contact hours: 0.25, which includes 0.25 hours of pharmacology credit

AAPA Credit Designation

Joint AccreditationPracticing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until March 24, 2023. PAs should only claim credit commensurate with the extent of their participation.

PA course advisor: Susan E. Kirk, PA-C, Baylor College of Medicine, Houston, Texas

IPCE Credit Designation
IPCEThis activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credits for learning and change.

Additional Information

Program Medium

This program has been made available online.